Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT04204057 · COMPLETED

Trial details

NCT number: NCT04204057
Sponsor: Rhizen Pharmaceuticals SA
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell

Start date: 2019-11-28
Primary completion: 2020-10-02
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.